Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ESG Rating

PPLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.3%1-day move

₹143.83

prior close

₹141.25

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.1+0.3+0.7-0.7+0.3-0.2+1.6+1.9+3.3+3.6+11.6+27.7+15.2+21.6

Up moveDown movePending

AI summary

Piramal Pharma received an ESG rating of 64 from NSE Sustainability Ratings and Analytics Limited for FY 2024-25, up from the previous score of 61. The improvement of 3 points reflects the company's ongoing commitment to sustainability and responsible operations. The rating was independently prepared by NSE Sustainability without engagement from the company, based on publicly available ESG data reported by the company. This is a voluntary ESG assessment and not a regulatory requirement.

Likely market impact

The improved ESG rating signals better governance practices and sustainability performance, which could positively influence ESG-focused institutional investors and long-term valuation perception, though it does not directly impact financial performance.